NFE2L2 and type 2 diabetes mellitus: Inhibition of GSK-3β was found to be therapeutic for type 2 diabetic glomerular injury as it allows NRF2 expression and subsequent suppression of oxidative stress, thus resulting in an improvement in podocyte injury and senescence (62).